The pre-seed round was led by QVentures with participation from angel investors including Simon Franks and Douglas Choi.
"I was let go from a previous role because I needed to work from home occasionally in order to accommodate my autoimmune disease. The fact that candidates do not know whether they will be able to work in a way that works for them is unacceptable. We are on a mission to bring a more flexible, inclusive way of working to as many people as we possibly can."
The Lincolnshire technology firm raised the capital to support team expansion and meet rising demand for its remote event planning software.
"I’m delighted to see Iventis make huge leaps forward in its growth. The company is recruiting talent from within the events industry, which has suffered immensely during the pandemic. We already have high-profile early adopters of the Iventis software, many of which are relying on its capabilities to reschedule and redesign their events."
The seed round drew backing from a group of digital and blockchain focused venture firms, including Alameda Research and CoinFund.
"Getting our FCA regulation in place and building the exchange platform were huge first milestones for us. But we obviously also needed the funding in place to meet our regulatory capital requirements to launch. To successfully close our seed raise, and beat our target in the process, was amazing – even more so when you consider the calibre of the VCs who have invested in us."
The seed round will fund domestic scaling ahead of international expansion.
"If 2020 made one thing very clear, it is the importance of the public sector working successfully together with private companies. We’re excited to partner with John, Taj, Carsten and the rest of the Stotles team to bring government procurement into the digital era,"
The Series A round was led by Northpond Ventures and Octopus Ventures to help bring the company manufacturing platform to market.
"Closing a significant Series A round, during these uncertain times, further validates Ori’s disruptive approach to fully automating cell and gene therapy manufacturing to increase throughput, improve quality, and decrease costs,"